1
|
Villacorta L, Gao Z, Schopfer FJ, Freeman BA, Chen YE. Nitro-fatty acids in cardiovascular regulation and diseases: characteristics and molecular mechanisms. Front Biosci (Landmark Ed) 2016; 21:873-89. [PMID: 26709810 DOI: 10.2741/4425] [Citation(s) in RCA: 34] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/06/2023]
Abstract
Electrophilic nitro-fatty acids (NO2-FAs) are endogenously formed by redox reactions of nitric oxide ((.)NO)- and nitrite ((.)NO2)- derived nitrogen dioxide with unsaturated fatty acids. Nitration preferentially occurs on polyunsaturated fatty acids with conjugated dienes under physiological or pathophysiological conditions such as during digestion, metabolism and as adaptive inflammatory processes. Nitro-fatty acids are present in free and esterified forms achieving broad biodistribution in humans and experimental models. Structural, functional and biological characterization of NO2-FAs has revealed clinically relevant protection from inflammatory injury in a number of cardiovascular, renal and metabolic experimental models. NO2-FAs are engaged in posttranslational modifications (PTMs) of a selective redox sensitive pool of proteins and regulate key adaptive signaling pathways involved in cellular homeostasis and inflammatory response. Here, we review and update the biosynthesis, metabolism and signaling actions of NO2-FAs, highlighting their diverse protective roles relevant to the cardiovascular system.
Collapse
Affiliation(s)
- Luis Villacorta
- Cardiovascular Center, Department of Internal Medicine, University of Michigan, North Campus Research Complex 26, 2800 Plymouth Road, Ann Arbor, MI 48109,,
| | - Zhen Gao
- Cardiovascular Center, Department of Internal Medicine, University of Michigan, North Campus Research Complex 26, 2800 Plymouth Road, Ann Arbor, MI 48109
| | - Francisco J Schopfer
- Department of Pharmacology and Chemical Biology, University of Pittsburgh, E1343 Thomas E. Starzl Biomedical Science Tower, 200 Lothrop Street, Pittsburgh, PA 15213
| | - Bruce A Freeman
- Department of Pharmacology and Chemical Biology, University of Pittsburgh, E1343 Thomas E. Starzl Biomedical Science Tower, 200 Lothrop Street, Pittsburgh, PA 15213
| | - Y Eugene Chen
- Cardiovascular Center, Department of Internal Medicine, University of Michigan, North Campus Research Complex 26, 2800 Plymouth Road, Ann Arbor, MI 48109
| |
Collapse
|
2
|
Jia Z, Sun Y, Yang G, Zhang A, Huang S, Heiney KM, Zhang Y. New Insights into the PPAR γ Agonists for the Treatment of Diabetic Nephropathy. PPAR Res 2014; 2014:818530. [PMID: 24624137 PMCID: PMC3927865 DOI: 10.1155/2014/818530] [Citation(s) in RCA: 30] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/18/2013] [Accepted: 12/16/2013] [Indexed: 02/07/2023] Open
Abstract
Diabetic nephropathy (DN) is a severe complication of diabetes and serves as the leading cause of chronic renal failure. In the past decades, angiotensin-converting enzyme inhibitors (ACEIs)/angiotensin II receptor blockers (ARBs) based first-line therapy can slow but cannot stop the progression of DN, which urgently requests the innovation of therapeutic strategies. Thiazolidinediones (TZDs), the synthetic exogenous ligands of nuclear receptor peroxisome proliferator-activated receptor- γ (PPAR γ ), had been thought to be a promising candidate for strengthening the therapy of DN. However, the severe adverse effects including fluid retention, cardiovascular complications, and bone loss greatly limited their use in clinic. Recently, numerous novel PPAR γ agonists involving the endogenous PPAR γ ligands and selective PPAR γ modulators (SPPARMs) are emerging as the promising candidates of the next generation of antidiabetic drugs instead of TZDs. Due to the higher selectivity of these novel PPAR γ agonists on the regulation of the antidiabetes-associated genes than that of the side effect-associated genes, they present fewer adverse effects than TZDs. The present review was undertaken to address the advancements and the therapeutic potential of these newly developed PPAR γ agonists in dealing with diabetic kidney disease. At the same time, the new insights into the therapeutic strategies of DN based on the PPAR γ agonists were fully addressed.
Collapse
Affiliation(s)
- Zhanjun Jia
- Department of Nephrology, Nanjing Children's Hospital, Nanjing Medical University, Nanjing 210008, China
- Institute of Pediatrics, Nanjing Medical University, Nanjing, China
- Key Pediatric Laboratory of Nanjing City, Nanjing 210008, China
| | - Ying Sun
- Department of Nephrology, Nanjing Children's Hospital, Nanjing Medical University, Nanjing 210008, China
- Institute of Pediatrics, Nanjing Medical University, Nanjing, China
- Key Pediatric Laboratory of Nanjing City, Nanjing 210008, China
| | - Guangrui Yang
- Institute for Translational Medicine and Therapeutics, University of Pennsylvania, Philadelphia, PA 19104, USA
| | - Aihua Zhang
- Department of Nephrology, Nanjing Children's Hospital, Nanjing Medical University, Nanjing 210008, China
- Institute of Pediatrics, Nanjing Medical University, Nanjing, China
- Key Pediatric Laboratory of Nanjing City, Nanjing 210008, China
| | - Songming Huang
- Department of Nephrology, Nanjing Children's Hospital, Nanjing Medical University, Nanjing 210008, China
- Institute of Pediatrics, Nanjing Medical University, Nanjing, China
- Key Pediatric Laboratory of Nanjing City, Nanjing 210008, China
| | | | - Yue Zhang
- Department of Nephrology, Nanjing Children's Hospital, Nanjing Medical University, Nanjing 210008, China
- Institute of Pediatrics, Nanjing Medical University, Nanjing, China
- Key Pediatric Laboratory of Nanjing City, Nanjing 210008, China
| |
Collapse
|